High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey

Table 2 Comparisons of HDL-cholesterol levels in the three antipsychotic groups with stratification by BMI for inpatients

			Olanzapine	Risperidone	Aripiprazole	p-value	Post-hoc (p-value)
HDL-cholesterol	BMI < 18.5	mg/dL	62.0 ± 20.5 (34)	58.6 ± 15.8 (55)	62.6 ± 21.6 (28)	0.490
	18.5 ≤ BMI < 25	mg/dL	54.1 ± 21.5 (137)	55.0 ± 16.2 (196)	58.2 ± 15.8 (68)	0.282
	BMI ≥ 25	mg/dL	43.8 ± 12.3 (47)	49.7 ± 15.0 (84)	54.7 ± 16.8 (25)	0.019	Olanzapine < Aripiprazole (0.023)

Data are shown as the mean ± SD (number of subjects)
Analyses of covariance among the three antipsychotics were performed for HDL-cholesterol with age, diastolic blood pressure, chlorpromazine-equivalent dosage and waist circumference as confounding variables
Post-hoc analyses were performed by the Bonferroni method
HDL high-density lipoprotein, BMI body mass index

ISSN: 1471-244X